Marco in Gastric Cancer

Marco offers oncologists and gastroenterologists updated evidence on gastric cancer, including HER2, PD-L1 and microsatellite instability classification, ESMO/NCCN guidelines and trial data on targeted therapies and immunotherapy. The AI agent enables natural language queries on the management of gastric and gastroesophageal junction adenocarcinoma.

FAQs

Frequently Asked Questions

Some answers to questions we often receive

Does Marco help interpret HER2 status in gastric cancer and its therapeutic implications?

Yes. Marco integrates HER2 positivity criteria in gastric cancer (IHC 3+ or IHC 2+/FISH amplified) and evidence for trastuzumab with chemotherapy (ToGA), trastuzumab deruxtecan in second line (DESTINY-Gastric01/02) and rebiopsy guidelines in progressed disease.

Which perioperative chemotherapy regimens does Marco recommend for gastric cancer?

Marco includes the comparison between FLOT (docetaxel, oxaliplatin, leucovorin, 5-FU) and ECF/ECX schemes based on FLOT4-AIO trial data, with indications per stage, performance status and HER2 status, and current ESMO recommendations for resectable disease.

How does Marco help in metastatic gastric cancer management in third line?

Marco synthesizes available third-line options: trifluridine/tipiracil, ramucirumab and options per biomarker including FGFR2b (bemarituzumab), HER2 (trastuzumab deruxtecan) and MSI-H (pembrolizumab), with available efficacy and safety evidence.

What does the evidence say about nivolumab in gastric cancer based on PD-L1 CPS?

Marco synthesizes CheckMate 649 data, CPS thresholds (≥5) for nivolumab plus chemotherapy indication in first line, differential benefit by CPS level and ESMO/NCCN criteria for use in metastatic gastric and GEJ adenocarcinoma.

Does Marco cover the TCGA molecular classification of gastric cancer?

Yes. Marco includes the TCGA molecular classification (EBV+, MSI, GS, CIN) and its prognostic and therapeutic implications, with special emphasis on the MSI-H subgroup and its immunotherapy response, integrating recent evidence and recommended molecular testing guidelines.

Does Marco include early gastric cancer and endoscopic resection criteria?

Marco covers endoscopic resection (EMR, ESD) criteria for early gastric cancer per Japanese and ESMO guidelines, key histological factors (size, submucosal invasion, differentiation) and recommended post-resection surveillance.

Access updated gastric evidence

Let's create the future together

Managing gastric cancer requires integrating HER2, PD-L1 and MSI for every patient against constantly updated ESMO/NCCN guidelines that no team can track manually.